Background {#Sec1}
==========

Very old patients (age ≥ 80 years) now comprise approximately one fourth of all intensive care unit (ICU) admissions in the United States and similarly in Europe, receive much more intensive medical treatment than in the past, and progressively survive even fatal critical illnesses \[[@CR1], [@CR2]\]. However, in view of enormous personal efforts of intensive care givers and increased economic costs due to prolonged and complicated ICU stays of octogenarians, proportionality of costs and resource usage came in focus \[[@CR2]\] with two main aspects: First, emergency triage process must be optimised and simplified to facilitate ICU admission for very old patients \[[@CR3], [@CR4]\]. Second, more scientific and clinical interest must be applied on all aspects of geriatric medicine to adapt existing risk-stratification data to daily clinical scenarios \[[@CR5], [@CR6]\].

In this context, a 9-point Clinical Frailty Scale (CFS) as an advancement of the Canadian 7-point CFS has been developed \[[@CR7]\]. Recently, the prospective, observational, European-ICU-network based VIP-1 study demonstrated that frailty is a significant factor reducing 30-day survival and that the 9-point CFS is an appropriate tool to assess this effect \[[@CR4]\]. The rationale behind scientific efforts in this field is explained by the very complex nature of circumscribing frailty to other specific medical problems \[[@CR8]\]. Consecutively, whereas physical frailty is a measurable clinical phenotype of increased vulnerability for developing adverse outcomes (e.g. disability and/or mortality) when exposed to a stressor, it is highly difficult to explain the current frailty status in an abbreviated and objective manner to another medical-professional.

As the largest study investigating the value of preadmission CFS in elderlies admitted to ICUs, the VIP-1 study was one of the first large studies highlighting the impact of assessing CFS as a herald for outcome in very old ICU patients \[[@CR4]\]. The advanced 9-point CFS, measured at a rapid diagnostic glance, showed even more robust outcome-foreshowing value compared to routinely used ICU indices like SOFA or APACHE-II score in VIP-1 \[[@CR4]\].

ICUs from 21 European countries and 3 Non-Europe countries participated in the VIP-1 study \[[@CR4]\]. The participating countries represent a broad range of different health care systems and philosophies, and less than 10% of included patients came from Germany. The recent Organisation for Economic Co-operation and Development (OECD) health report emphasized the differences in health status and life expectancy in the participating countries, leading to varying challenges \[[@CR9]\]. These factors most likely affect case mixes and intensity of treatment provided in ICUs of the different countries participating in the VIP-1 trial. Indeed, VIP-1 showed regional differences in the frequency of frail patients admitted to ICUs. Consequently, the conclusions drawn by the multi-national VIP-1 study might not be transferable to the individual health care situation of each participating country. In this current study, we undertook a multicentre sub-analysis of the German VIP-1 cohort and aimed to test if the predictive value of CFS is still robust on a national level in very diversified and high-tech German ICUs.

Methods {#Sec2}
=======

Study sample {#Sec3}
------------

This analysis is a sub-analysis of the 20 German ICUs participating in the prospectively realised observational multicentre European VIP-1 study (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR4]\]. The aim of the study was to investigate whether the CFS is usable for risk stratification in octogenarians admitted to diversified and high tech German ICUs. The VIP-1 study was coordinated by the Health Services Resource and Outcome (HSRO) section of the European Society of Intensive Care Medicine (ESICM) and was registered on ClinicalTrials.gov (ID: NCT03134807; first posted on May 1st 2017 after recruitment completed). All patients at least 80 years of age admitted to the participating ICUs for any cause were eligible for documentation after giving written informed consent (by themselves or responsible advisor). Data from not more than 20 consecutive patients per ICU were collected.Fig. 1Participating ICUs. Participating ICUs are marked. The number of enclosed patients is indicated for each participating ICU

Ethical approval was obtained from each study side (Additional file [1](#MOESM1){ref-type="media"}: Ethic committees). Patients were recruited between October 2016 and February 2017.

Data collection and scoring systems {#Sec4}
-----------------------------------

Initial Simplified Acute Physiology Score II (SAPS II), Acute Physiology And Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores were calculated by treating physicians within 24 h after admission as reported previously \[[@CR10]--[@CR12]\]. Length of stay (LOS) was recorded in hours, allowing calculation of LOS in 24-h periods rather than in calendar days. It was recorded whether patients were subjected to invasive or non-invasive ventilation, vasoactive drugs were administered or renal replacement therapy was applied during their ICU stay. However, the duration of those intensive therapies was not recorded. The database was located on a secure server in Aarhus University, Denmark.

Frailty {#Sec5}
-------

Frailty was defined according to the Clinical Frailty Scale (CFS). The CFS is an easy and intuitive determinable categorisation tool based on simple visual descriptions \[[@CR7]\]. The CFS divides patients into 9 classes from very fit (CFS = 1) to terminally ill (CFS = 9). The status of the patients before hospital admission was obtained from the patients or their relatives.

Statistical analyses {#Sec6}
--------------------

Statistical analyses were performed using SPSS (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY, USA). For statistical analyses, patients were stratified according to their admission status (planned vs. unplanned). The patients with unplanned admission were further divided into the following three groups: acute medical, acute surgery and trauma. Patients were followed for 30 days after ICU admission. Baseline patient characteristics, treatment and outcomes were compared between two frailty groups based on the CFS: not-frail (CFS 1--4) and frail (CFS 5--9) as used in previous publications \[[@CR6]\].

Additionally, for characterisation of patients according to 30-day survival and according to the type of admission, frailty status was defined as not frail (CFS 1--3), pre-frail (CFS 4) and frail (CFS 5--9) \[[@CR4]\]. Frailty was also analysed using the whole scale as ordinal data. For continuous variables, normally distributed data is given in mean ± standard deviation and compared by student's t-test. Non-normally distributed data is shown as median with inter-quartile-range and compared by Mann-Whitney-U-Test or Kruskal-Wallis-Test as appropriate. Categorical variables were described by counts and percentages. Differences between groups were calculated by Chi-square test. The impact of age, gender, APACHE II, SAPS II, Sofa-score, type of admission (planned vs. unplanned, acute medical vs. acute surgery, acute surgery vs. trauma and acute medical vs. trauma) and frailty on 30-day mortality was estimated using logistic regression analyses. Variables with a *p*-value below 0.10 in univariate logistic regression analysis were included in the multivariate logistic regression model to estimate the adjusted impact of frailty on 30-day mortality. *P*-values \< 0.05 were considered significant.

Results {#Sec7}
=======

In this sub-analysis of the European VIP-1 study cohort, a total number of 308 patients of 80 years of age or older admitted to 20 German ICUs were analysed. Participating ICUs collected data from 3 to 20 patients (Fig. [1](#Fig1){ref-type="fig"}).

Median age was 84 \[IQR 82--87\] years and 50% of the patients were male. Median LOS in the ICU was 3.1 \[IQR 1.1--8.1\] days. ICU-mortality was 17.3% and 30-day mortality was 31.2% (Table [1](#Tab1){ref-type="table"}). Out of the analysed ICU patients, 31.5% had planned admissions due to post surgery care. The other patients were admitted due to acute medical reasons (52.6%), trauma (10.7%) or acute surgery (5.2%) as shown in Table [1](#Tab1){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. Respiratory and/or circulatory failure was the most frequent cause for admission. Use of life sustaining treatments is shown in Table [1](#Tab1){ref-type="table"}. In 26.6% of the patients none of the ICU procedures were recorded. Frailty according to the CFS could be determined for all patients.Table 1Patient characteristics according to the frailty statusFrailty statusOverallNot frail (CFS 1--4)Frail (CFS 5--9)*p*-valueNumber of admissions308 (100%)143 (46.4%)165 (53.6%)Age84 \[82--87\]82 \[81--86\]85 \[82--88\]\< 0.001Male164 (50%)79 (55.2%)75 (45.5%)0.09APACHE II18 \[12--26\]15 \[12--25\]19 \[12--26\]0.18SAPS II39 \[29.5--51\]37 \[29--48\]42 \[30--55\]0.17SOFA Score6 \[3--10\]6 \[3--9\]7 \[4--10\]0.016Cause of admission Acute medical162 (52.6%)58 (40.6%)104 (63%)\< 0.001 Acute surgery16 (5.2%)8 (5.6%)8 (4.8%)0.77 Trauma33 (10.7%)14 (9.8%)19 (11.5%)0.63 Elective surgery97 (31.5%)63 (44.1%)34 (20.6%)\< 0.001ICU length of stay (days)3.1 \[1.1--8.1\]2.9 \[1--7\]3.4 \[1.4--9.5\]0.21Use of life sustaining treatments Non-invasive ventilation104 (33.8%)48 (33.6%)56 (33.9%)0.95 Mechanical ventilation141 (45.8%)59 (41.3%)82 (49.7%)0.14 Vasoactive drugs189 (61.4%)82 (57.3%)107 (64.8%)0.18 Renal replacement therapy59 (19.2%)26 (18.2%)33 (20%)0.69Treatment withheld41 (13.3%)11 (7.7%)30 (18.2%)0.01Treatment withdrawn36 (11.7%)10 (7%)26 (15.8%)0.02ICU mortality53 (17.3%)16 (11.3%)37 (22.4%)0.0130-day mortality84 (31.2%)23 (18.4%)61 (42.4%)\< 0.001Fig. 2Association of the Clinical Frailty Scale with 30-day mortality in acute admitted patients. Distribution of frailty in acute and elective admitted Patients (**a**). Association of frailty with 30-day mortality (**b**). Patients were divided into three groups according to their frailty status: fit (CFS 1--3), pre-frail (CFS 4) and frail (CFS 5--9). CFS: Clinical Frailty Score ranging from 1 (not frail) to 9 (terminally ill)

Frail patients are characterized by frailty score ≥ 5 and not frail patients by a frailty score ≤ 4. Data are presented as median and interquartile range \[IQR\] or frequency and percentages (n, %). ICU: Intensive Care Unit. CFS: Clinical Frailty Score ranging from 1 (not frail) to 9 (terminally ill).

Planned admitted patients had a lower CFS compared to acute admitted patients and showed a lower ICU- and 30-day mortality (Fig. [2](#Fig2){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). Data are presented as median and interquartile range \[IQR\] or frequency and percentages (n, %). ICU: Intensive Care Unit. CFS: Clinical Frailty Score ranging from 1 (not frail) to 9 (terminally ill).Table 2Patient characteristics according to the cause of admissionAdmission unplannd vs. plannedUnplannedPlanned*p-*valueCause of admissionAcute medicalAcute surgeryTraumaElective surgeryElective vs acuteSample size162 (52.6%)16 (5.2%)33 (10.7%)97 (31.5%)Age84 \[82--86\]83 \[81--89\]86 \[83--90\]83 \[81--87\]0.33Male82 (50.6%)12 (75%)13 (39.4%)47 (48.5%)0.71APACHE II20 \[15--27\]18 \[14--18\]18 \[13--24\]14 \[10--19\]0.001SAPS II42 \[34--53\]46 \[42--46\]31 \[23--46\]35 \[26--49\]0.03SOFA Score8 \[4--10\]11 \[6--13\]6 \[4--9\]4 \[3--7\]\< 0.001Frailty status Fit (CFS 1--3)30 (18.5%)7 (43.8%)8 (24.2%)28 (28.9%)0.15 Pre-frail (CFS 4)28 (17.3%)1 (6.3%)6 (18.2%)35 (36.1%)\< 0.001 Frail (CFS 5--9)104 (64.2%)8 (50%)19 (57.6%)34 (35.1%)\< 0.001ICU length of stay (days)5 \[2.0--10.5\]6.2 \[2.1--17.6\]3 \[1.3--6.8\]1.4 \[1--3.5\]\< 0.001Use of life sustaining treatments Non-invasive ventilation63 (38.9%)6 (37.5%)10 (30.3%)25 (25.8%)0.04 Mechanical ventilation75 (46.3%)13 (81.3%)20 (60.6%)33 (34%)0.005 Vasoactive drugs110 (67.9%)15 (93.8%)20 (60.6%)44 (45.4%)\< 0.001 Renal replacement therapy41 (25.3%)4 (25%)1 (3%)13 (13.4%)0.08Treatment withheld29 (17.9%)3 (18.8%)9 (27.3%)0 (0%)\< 0.001Treatment withdrawn27 (16.7%)3 (18.8%)4 (12.1%)2 (2.1%)\< 0.001ICU mortality39 (24.1%)4 (25%)6 (18.2%)4 (4.2%)\< 0.00130-day mortality61 (41.8%)6 (50%)10 (38.5%)7 (8.2%)\< 0.001

For further evaluation of the impact of frailty, patients were divided into two groups according to their frailty status as depicted in Table [1](#Tab1){ref-type="table"}. Frail patients showed higher values for organ failure and ICU treatment was more often withhold or withdrawn. However, there was no significant difference between frail and non-frail patients with regard to the APACHE-II and SAPS-II scores. ICU mortality and 30-day mortality were significantly higher for frail patients compared to non-frail patients (Table [1](#Tab1){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). Patients surviving 30 days after ICU admission were less frail, stayed shorter in ICU, got less invasive treatment and treatment was less often withheld or withdrawn (Table [3](#Tab3){ref-type="table"}). Data are presented as interquartile range \[IQR\] or absolute numbers and percentages (n, %). ICU: Intensive Care Unit. CFS: Clinical Frailty Score ranging from 1 (not frail) to 9 (terminally ill).Table 3Patient characteristics according to the survival status30 day survival statusSurvivorsNonsurvivors*p* valueNumber of admissions185 (68.8%)84 (31.2%)Age83 \[81--86\]85 \[81--88\]0.06Male85 (45.9%)47 (56%)0.13APACHE II17 \[12--23\]25 \[18--32\]\< 0.001SAPS II37 \[29--50\]48 \[39--61\]0.001SOFA Score6 \[3--9\]8 \[5--11\]\< 0.001Frailty status Fit (CFS 1--3)52 (28.1%)12 (14.3%)0.014 Pre-frail (CFS 4)50 (27%)11 (13%)0.011 Frail (CFS 5--9)83 (44.9%)61 (72.6%)\< 0.001Cause of admission Acute medical85 (45.9%)61 (72.6%)\< 0.001 Acute surgery6 (3.2%)6 (7.1%)0.15 Trauma16 (8.6%)10 (11.9%)0.4 Elective surgery78 (42.2%)7 (8.3%)\< 0.001ICU length of stay (days)2.7 \[1--8\]5.2 \[2.2--9.8\]0.012Use of life sustaining treatments Non-invasive Ventilation69 (37.3%)28 (33.3%)0.53 Mechanical ventilation74 (40%)58 (69%)\< 0.001 Vasoactive drugs107 (57.8%)66 (78.6%)0.001 Renal replacement therapy31 (16.8%)27 (32.1%)0.004Treatment withheld8 (4.3%)32 (38.1%)\< 0.001Treatment withdrawn1 (0.5%)34 (40.5%)\< 0.001ICU mortality0 (0%)53 (63.1%)\< 0.001

Univariate regression analysis showed that frailty measured by the CFS as well as APACHE II, SAPS II and SOFA scores and the cause of admission (unplanned vs. planned) were associated with higher 30-day mortality. In a multivariate regression analysis the cause of admission was the strongest predictor for 30-day mortality (OR 5.74) after adjusting for other covariates. Thus, mortality was 5.74 times higher in acute admitted patients compared to elective admitted patients. Moreover, the CFS independently predicted 30-day mortality in the multivariate regression analyses (OR 1.44). Thus, for each point increase of the CFS, mortality increased by 1.4 times. However, the APACHE II, SAPS II and SOFA scores failed to predict 30-day mortality in a multivariate regression analysis (Table [4](#Tab4){ref-type="table"}).Table 4Survival analyses: Univariate and multivariate logistic regression analysesParameterUnivariate predictorMultivariable predictor modelOR95% CI*p* valueAOR95% CI*p* valueAge (per year increase)1.069\[0.999;1.114\]0.0531.040\[0.920; 1.177\]0.531Male0.669\[0.398; 1.124\]0.13APACHE II (per point increase)1.101\[1.046; 1.158\]\<0.0011.053\[0.982; 1.129\]0.149SAPS II (per point increase)1.024\[1.006; 1.043\]0.011.007\[0.973; 1.043\]0.672SOFA Score (per point increase)1.150\[1.075; 1.231\]\<0.0011.072\[0.914; 1.259\]0.392Type of admission Acute vs. elective8.019\[3.507; 18.333\]\<0.0015.744\[1.186; 27.811\]0.030 Acute medical vs acute surgery0.718\[0.221; 2.332\]0.581 Acute surgery vs. trauma1.600\[0.402; 6.361\]0.504 Acute medical vs. trauma1.148\[0.488; 2.702\]0.752Frailty Frailty (per point increase)1.410\[1.187; 1.675\]\<0.0011.437\[1.052; 1.964\]0.023 Frail (CFS 5-9)3.259\[1.861; 5.708\]\<0.001 Pre-frail (CFS 4)0.407\[0.200; 0.829\]0.013 Fit (CFS 1-3)0.426\[0.214; 0.850\]0.015

Impact of the different factors on 30-day mortality in a univariate model is presented in the left part of the table. Factors with a *p*-value below 0.10 in a univariate logistic regression analysis were included into the multivariate model shown in the right part of the table. Impact of the factors on 30-day mortality is presented as Odd's Ratio (OR) in the univariate model or as adjusted Odd's Ratio (AOR) in the multivariate model respectively, and 95% Confidence Interval (95% CI). CFS: Clinical Frailty Score ranging from 1 (not frail) to 9 (terminally ill).

Discussion {#Sec8}
==========

This multicentre analysis of the German VIP-1 cohort \[[@CR4]\] focussing on a large cohort of more than 300 very old patients admitted to 20 German ICUs showed that frailty measured by the 9-point CFS \[[@CR4]\] is a valuable predictor of ICU- and 30-day mortality for very old patients admitted to highly diversified and high-tech German ICUs. These findings complement the recent analyses of the multi-national, prospective European VIP-1 cohort \[[@CR4]\]. In previous publications, conducted mainly in single centres, huge differences of ICU survival rates among octogenarians ranging from 14 to 46% have been described \[[@CR13], [@CR14]\]. This divergence can most likely be explained by case mix differences. Thus, the multi-national European VIP-1 study showed that in central, northern and eastern Europe a higher percentage of the admitted patients were frailer than in southern and western European countries \[[@CR4]\]. This finding is also reflected by the recent OECD health report pointing out differences in health care systems in the OECD countries \[[@CR9]\]. Our analysis of very old patients in German ICUs showed an ICU mortality of 17.3% and a 30-day mortality of 31.2% similar to the multi-national VIP-1 cohort with 22.1 and 32.4% and to a Canadian cohort with 21.8 and 35% \[[@CR15]\], respectively. However, despite high mortality rates, it is difficult to identify patients at risk among that vulnerable cohort since commonly used scoring systems for prediction of ICU outcome were developed for younger cohorts and are not reliable for use in the very old \[[@CR16]\]. Thus, in contrast to the results of the multi-national VIP-1 cohort, APACHE II, SAPS II and the SOFA score failed to predict 30-day mortality in a multivariate regression analysis on our multicentre cohort of very old patients in German ICUs. Recently, it was suggested that frailty is correlated with mortality in very old patients and that quantification of frailty might predict the outcome of very old patients admitted to ICUs. Frailty is defined as a condition of clinical vulnerability associated with age dependent reduction of physiological reserves \[[@CR17]\]. Different scores for the assessment of frailty were developed and their ability for the prediction of adverse outcomes including decline in functional performance, prolonged length of stay, institutionalisation, and mortality in geriatric patient collectives was confirmed \[[@CR4], [@CR18]--[@CR22]\]. Using the previously reported 9-point CFS \[[@CR4]\], we could show that increased frailty was independently associated with intra-ICU and 30-day mortality in a multicentre cohort of very old patients admitted to German ICUs. Thus, our data confirmed the observations of previous studies from Europe \[[@CR4]\] and America \[[@CR23]\] and proofed the usability of the CFS for risk stratification of octogenarians in German ICUs. The only parameter that was stronger associated with 30-day mortality than the frailty status was the type of admission (planned vs. unplanned). That observation might be caused by a selection bias since our analyses revealed that electively admitted patients were less frail and showed lower APACHE II, SAPS II and SOFA scores. Furthermore, health status of patients selected for elective surgery could be optimized prior to ICU admission. In contrast to the analysis of the multi-national European VIP-1 cohort \[[@CR4]\], our sub-analysis of the German VIP-1 cohort revealed no independent impact of age, gender or the SOFA score on 30-day mortality in a multivariate regression analysis. This important difference between the multi-national VIP-1 cohort comprising patients treated in different healthcare systems with diverging philosophies and financial resources and our more homogeneous German sub-cohort is most likely caused by the above mentioned inhomogeneity of the multi-national cohort. Thus, in contrast to the analysis of the multi-national VIP-1 cohort, our analysis among very old patients admitted to German ICUs showed that in octogenarians and nonagenarians not chronologic age but the bioenergetics state, stratified by the CFS, is a strong predictor of mortality.

The strengths of our study include its prospective multicentre character and the relatively high number of included patients. Time dependent confounders were minimized by limiting recruiting time to 8 months, thus time dependent confounders could be minimalized.

However, this study has limitations. No data on the proportion of included patients in relation to all ICU admissions nor data on patients that were not admitted to ICU due to triage decisions were recorded. For the sake of feasibility, neither long-term survival nor the functional status of the patients after ICU discharge were assessed. The used 9-point frailty scale is subjective with potentially high inter-rater variability. Nonetheless, in the context of acute ICU admission of vulnerable patients it is likely to be more feasible and easier to access than more objective scoring systems.

Conclusion {#Sec9}
==========

In conclusion, the CFS is an easy determinable valuable tool for the prediction of mortality in very old patients, thus it can facilitate decision making for intensive care givers in Germany.
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APACHE

:   Acute Physiology and Chronic Health Evaluation (3 aspects: age points + acute physiology score + chronic health score)

CFS

:   Clinical Frailty Scale (from 1 to 9; 1 = very fit / 5 = mildly frail / 9 = terminally ill)

ICU

:   Intensive Care Unit

SAPS

:   Simplified Acute Physiology Score

SOFA

:   Sequential Organ Failure Assessment Score

VIP-1

:   The Very Old Intensive Care Patient Trial 1
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